The design of peptidomimetics [1] of peptide-protein or protein-protein interactions needs to take into consideration the specific amino acid interactions between the ligand and its protein receptor. [2] Peptide turns play an essential role in many recognition events, [2] including receptor recognition in the most abundant receptor class, GPCRs, [3] with many bioactive peptides adopting -or -turn conformations. [3] Peptide turn mimetic strategies range from local peptide amino acid modification to the development of small molecule turn mimetics. [1] [2] 4] However, these approaches often generate overly flexible scaffolds that reduce receptor selectivity and potency [5] or require complex synthetic strategies. [6] In the absence of precise three-dimensional structures of ligands in complex with membrane proteins [7] the introduction of conformational constraints (cyclization and turn mimetics) is a promising approach to developing bioactive peptidomimetics. [8] Such strategies have produced clinically relevant [9] and potent peptidomimetics of somatostatin, angiotensin II receptor antagonists, integrin inhibitors, and oxytocin and vasopressin analogues. [3] To date, there is no design strategy that can generate readily accessible diverse sets of turn mimetics with properties appropriate for further drug development. Here, we describe a broadly applicable combinatorial chemistry approach that addresses some of these shortcomings and use it to design a norepinephrine reuptake inhibitory peptide mimetic of exceptional metabolic stability.
Scheme 1 A: NMR structure of -conopeptide 1 [10] highlighting the pharmacophore of this norepinephrine reuptake inhibitor B: Pharmacophore (GYKL) of 1 represented by an inverse turn; C: Design of N-to C-cyclic vicinal disulfide constrained peptide turn mimetic with x indicating the modification sites.
The -conotoxin MrIa (1) (Scheme 1A: sequence NGVCCGYKLCHOC) non-competitively inhibits the norephinephrine transporter (NET) and a closely related analog Xen2174 (1a) (sequence UGVCCGYKLCHOC where U=pyroglutamyl) is currently under development for the treatment of severe pain. [10a, 11] These -conotoxins contain the sequence GYKL that is essential for high affinity NET inhibition. [10a] Structural studies reveal that the rigid framework formed by two disulfide bonds between the cysteine residues (1-4, 2-3) induces a -hairpin with two antiparallel strands (Scheme 1A) connected by an inverse -turn comprising GYK, [10b] further constraining the pharmacophore (Scheme 1B).
Our initial design strategy involved incorporating the YKL pharmacophore within a cyclic peptide. To minimize the size of the ring and restrict flexibility, we incorporated a vicinal disulfide bond as a further constraint (Scheme 1C) and then varied the amino acids ( Figure 1C indicated as X) adjacent to the YKL pharmacophore to modulate structure and gain additional structure-activity information. Vicinal disulfide bonds are found in the active sites of enzymes, [12] near the binding site of receptors [12] [13] as well as in toxin peptides.
[14]
In proteins, this unique 8-membered ring prefers a type VIII turn with a distorted trans-amide conformation, [12] while in small model peptides cis or trans amide bond conformations are observed [15] In receptors, vicinal disulfide bonds may function as regulatory switches through manipulation of their oxidation state. [12, 16] We used intramolecular native chemical ligation (NCL) to access these designed turn mimetics. Conveniently, the NCL approach [17] allows access to a diverse range of cyclopeptides without the need for complex side chain protection strategies. To produce cyclic peptide libraries where X is variable (Scheme 1C) we employed Boc chemistry to synthesize the peptide thioesters necessary for the NCL cyclization. Though Boc-chemistry is well established and robust, throughput is limited by the final HF cleavage step. [17] To overcome this bottleneck we employed the combination of a safety catch amide linker and a resin support that is compartmentalized to allow easy manual handling and sorting (Scheme 2).
Starting with Mimotopes aminomethylated lanterns, a safety catch linker (SCAL) [18] was attached (2), followed by a Gly spacer and a mercaptopropionic acid linker. The thiol resin (3) was then used to produce the cyclic peptide libraries ( Figure 1C ) of type 8 (Scheme 2) in a split and mix fashion using standard peptide coupling conditions. After chain assembly was complete the thioester-loaded lanterns 4 were transferred together into a single HF cleavage vessel, which allowed removal of the side chain protecting groups, while the HF stable SCAL maintains the deprotected thioester on resin (4  5). The free thioester peptides 7 are obtained after sorting the lanterns into individual vials and addition of NH4I/DMS/TFA, which both reduces the SCAL sulfoxide (5  6) and renders the substituted benzhydrylamine linkage TFA labile, while oxidizing the vicinal disulfide bond to yield 7. [18] [19] The crude peptide-thioesters 7 were readily N-C cyclized in a 0.1 M NH4HCO3 buffer to yield (8) , the formation of which is autocatalyzed by the thiol released from the linker moiety during cyclization (See SI) Cyclic peptides 8a-8j were tested on a functional human norepinephrine transporter assay. Table 1 show that our design strategy successfully generated active mimetics of peptide 1, with the vicinally constrained cyclic heptapeptide 8a (CCGYKLG) equipotent to 1. Other analogs showed that we could manipulate potency by varying either the pharmacophoric residues or residues at positions X. To confirm that the vicinal disulfide bond is a structurally essential element for the cyclopeptide bioactivity, we reduced peptidomimetic 8a using TCEP and S-alkylated the cysteine residues with iodo-acetamide or iodomethane. The cyclic and S-alkylated products (9 and 10, Table 1) showed ~ 10-fold loss in activity, confirming the importance of the vicinal disulfide bond.
The structure of mimetic 8a in water (with 5% D2O) was determined by 1D 1 H-NMR and 2D NMR (TOCSY, NOESY, 1 H- 13 C HSQC) at a 1 H frequency of 900 MHz. Structure calculations were performed using the torsion angle dynamics approach of CYANA v3.0 [20] with automated nOe assignments. The nOe data was supplemented with backbone angle restraints based on 1 H and 13 C chemical shift data using TALOS+. [21] Sufficient nOe interactions enabled determination of a high-resolution structure of 8a. ( Figure  3A ) The vicinal disulfide bond in 8a results in a distorted trans-amide bond (41° from planarity), consistent with previous reports [22] (see also SI), which allowed formation of a hydrogen bond between Cys1-(CO) and Tyr4-(NH) that stabilized the CCGY-region in a -turn conformation ( Figure  3A) . Superposition of the YKL side chains of the parent compound 1 and the mimetic 8a revealed a high degree of overlap, suggesting that the mimetic retained the pharmacophore of 1 (RMSD over C atoms: 0.06 Å and C  0.22 Å, see Scheme 3B). In contrast, NMR analysis of the reduced and methylated 10 produced results consistent with a random coil, with no long range interactions, confirming that the vicinal disulfide bond provided a key structural constraint (SI). Table 1 : Norepinephrine reuptake inhibition (IC50  SEM) of vicinal disulfide constrained cyclic peptidomimetics (8a-8j), and -conopeptides 1 (1-4, 2-3 disulfide bond). Reduced and alkylated products 9, and 10 show decreased activity due to loss of the vicinal disulfide constraint.
Entry Sequence IC50 [M]
1 NGVCCGYKLCHOC [a] 2.45 ± 0.07 1a UGVCCGYKLCHOC [a] 2.55 ± 0.18 
49 ± 8 [a] (U = pyroglutamic acid, O = hydroxyproline),
[e] SMe = S-methylated cysteine
We further evaluated the suitability of analogues 8a and 8b as clinical leads. Unlike many peptides, we found that peptidomimetic 8a which is stable in trypsin (SI) and both 8a and 8b had exceptional stability in plasma that was not derived from serum albumin adsorption (SI) and remained predominantly intact for at least 50 h (Scheme 4). This stability can be attributed to the N to C cyclization [23] but the stability of the disulfide bond (redox potential of 8a -313mV see SI), which forms readily even under highly acidic conditions, may also contribute. This redox potential of 8a compared well with values reported for similar transoid vicinal disulfides [15] and is surprisingly more stable than many natural occurring disulfides. [24] We also established (SI) that the mimetic 8a inhibits NET in isolated rat brain slices (IC50 = 4.2 µM), indicating its stability not only in plasma but also in brain tissue.
In conclusion, this work describes the synthesis of peptide turn mimetics that combines a novel high throughput combinatorial strategy for peptide thioesters and their subsequent conversion into backbone cyclic peptides containing a vicinal disulfide constraint. Our results demonstrate that it is possible to graft an active peptide turn onto a vicinal disulfide constrained cyclic scaffold to both improve chemical and biological stability while maintaining full potency. Although this work is based on a well characterized peptide turn [10a] , we believe that this approach can be broadly applied to the design of other turn mimetics where such knowledge is unavailable. This is due to the fact that the topological orientation of pharmacophore side chains largely determines bioactivity rather then the specific turn type. [25] Scheme 3 A: NMR structure of vicinal disulfide constrained cyclic peptidomimetics 8a. B: superposition of the pharmacophore region of -conopeptide (1, grey) with the mimetic 8a (red).
Scheme 4:
Plasma stability of cyclic peptidomimetics 8a and 8b compared to clinical candidate 1a.
Experimental Section
Experimental details are described in the Supporting Information. 
